Q-omics provides the consensus-scored MIR1271 profile across patient tissues and cancer cell-line models. MIR1271 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR1271 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR1271 RNA expression shows 8,160 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where MIR1271 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1271 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1271 survival associations across molecular data types. MIR1271 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1271 RNA expression–survival associations across cancer types. High MIR1271 expression shows unfavorable associations in MESO, BLCA, READ, DLBC, PAAD and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR1271 RNA expression.
This table summarizes MIR1271 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1271. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1271 shows lower tumor expression in KIRP and higher tumor expression in KIRC. The KIRC box plot shows higher MIR1271 RNA expression in tumor versus normal tissue (log2 FC = +0.193, t-test p = .001).
This table shows molecular features associated with MIR1271 in patient tissues and cancer cell lines. In patient samples, MIR1271 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
